引用本文:[点击复制]
[点击复制]
【打印本页】 【在线阅读全文】【下载PDF全文】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 117次   下载 28 本文二维码信息
码上扫一扫!
重组人脑利钠肽和硝酸甘油治疗难治性心力衰竭的疗效及安全性分析
刘文婷,胡立群,李红旗,张梦媛
0
(中国科技大学附属第一医院)
摘要:
【摘要】 目的 观察重组人脑利钠钛和硝酸甘油治疗难治性心力衰竭的疗效和安全性。方法 选取2018年1月~〖JP〗2019年3月就诊于本院的难治性心力衰竭患者164例,入选患者随机分为对照组和观察组,其中对照组84例应用硝酸甘油治疗,观察组80例应用重组人脑利钠钛治疗。比较两组患者治疗前后N端前脑钠肽(NTproBNP)、左室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)、总有效率及两组患者呼吸困难、周身水肿、肺部啰音的改善情况。安全性评估采用用药过程中及用药后定期测定血压、心率,并对治疗过程中所有不良反应进行记录。结果 治疗后两组NTproBNP、LVEF、LVEDD、LVESD较治疗前均有改善,且观察组治疗前后LVEDD、LVESD改善较对照组更明显(P<0.05);观察组总有效率优于对照组(P<0.05);观察组呼吸困难、周身水肿、肺部啰音程度的改善均优于对照组(P<0.05);两组NTproBNP、LVEF改善比较差异无统计学意义(P>0.05)。两组药物相关的不良反应比较差异无统计学意义(P>0.05)。结论 重组人脑利钠钛较硝酸甘油更能显著改善难治性心力衰竭患者的心功能和全身症状,其安全性与硝酸甘油类似。
关键词:  难治性心力衰竭  重组人脑利钠钛  硝酸甘油  心功能  疗效  安全性
DOI:
基金项目:安徽省自然科学基金项目(1808085MH281)
Comparison of the effects of intravenous recombinant human brain natriuretic peptide and nitroglycerin in patients with refractory heart failure
LIU Wenting,HU Liqun,LI Hongqi,ZHANG Mengyuan
(The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China)
Abstract:
【Abstract】 Objective To compare the efficacy and safety of recombinant human brain natriuretic titanium (rhBNP) and nitroglycerin (NIT) in treating people with refractory heart failure. Methods 164 patients characterized of refractory heart failure were enrolled in this study. They were randomly assigned to receive NIT (n=84) or rhBNP (n=80). NTproBNP, LVEF, LVEDD, LVESD, overall response rate, the scores of dyspnea, lung rales, systemic edema before and after treatment were compared. Blood pressure and heart rate were measured regularly during and after the administration, and all adverse reactions were recorded. Results NTproBNP, LVEF, LVEDD and LVESD were improved after both rhBNP and NIT treatments. LVEDD and LVESD in rhBNP group were more significantly improved than that of NIT group (P<0.05). The overall response rate and the scores of dyspnea, lung rales, systemic edema in the rhBNP group were significantly better than that NIT group (P<0.05). There were no significant difference in NTproBNP or LVEF between the two groups (P>0.05). There was no significant difference in drugrelated adverse reactions between the two groups (P>0.05). Conclusion Compared with NIT, rhBNP can significantly improve cardiac function and systemic symptoms in patients with refractory heart failure, and its safety is similar to that of NIT.
Key words:  Refractory heart failure  Recombinant Human Brain Natriuretic Peptide  Nitroglycerin  Cardiac function  Efficacy

用微信扫一扫

用微信扫一扫